Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
Both will join the six-member Executive Committee effective January 1, 2024.
- Both will join the six-member Executive Committee effective January 1, 2024.
- “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission.
- Notably, he was instrumental in establishing Santhera’s European commercial operations and successfully launching the rare disease product RAXONE® in Europe which was later divested to Chiesi Group.
- Before joining Santhera, Geert Jan held positions as Medical Director, Business Unit Director and General Manager in start-up teams in Serono, Actelion and InterMune.